Drug intelligence / Profile preview

chlorphenamine + paracetamol + phenylephrine (TCF Pharmaceuticals)

Development stage
Phase 3
Lead developer
TCF Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Fepacold is an oral fixed-dose combination medication developed and marketed by TCF Pharmaceuticals for the symptomatic relief of the common cold, influenza, and upper respiratory allergies. It is formulated in multiple oral dosage forms, including drops, suspension, and tablets. The product contains three active ingredients: paracetamol (acetaminophen), a mild analgesic and antipyretic; phenylephrine, a sympathomimetic nasal decongestant; and chlorphenamine (chlorpheniramine), a first-generation antihistamine. Paracetamol reduces fever and relieves pain by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine acts as an agonist on alpha-1 adrenergic receptors to constrict blood vessels in the nasal passages, thereby reducing swelling and congestion. Chlorphenamine blocks histamine H1 receptors to alleviate allergic symptoms such as sneezing, runny nose, and watery eyes.

Brand names
Fepacold
Other names
acetaminophen + chlorphenamine + phenylephrineacetaminophen + chlorpheniramine + phenylephrinechlorphenamine + paracetamol + phenylephrinechlorphenamine maleate + paracetamol + phenylephrine hydrochloridechlorpheniramine + paracetamol + phenylephrinechlorpheniramine maleate + paracetamol + phenylephrine hydrochloride
02

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on chlorphenamine + paracetamol + phenylephrine (TCF Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorphenamine + paracetamol + phenylephrine (TCF Pharmaceuticals).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call